Aging of the Human Neuromuscular System: Pathological Aspects

Muscle Aging, Inclusion-Body Myositis and Myopathies

Volumn , Issue , 2011, Pages 3-32

  Engel, W King ^a   Askanas, Valerie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aging muscle; Cachectic muscle atrophy; Denervation muscle atrophy; Neuropathy in aging; Type 2 muscle fiber atrophy

Indexed keywords

EID: 84885540751     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444398311.ch1     Document Type: Chapter

References (114)

1. EngelWK, Warmolts JR. (1971) Myasthenia gravis: a new hypothesis of the pathogenesis and a new form of treatment. Ann NY Acad Sci 18, 72-87.
2. Engel WK, Warmolts JR. (1973) The motor unit: Diseases affecting it in toto or in portio. In: Desmedt JE (ed.). New Developments in Electromyography and Clinical Neurophysiology. Karger, Basel, pp. 141-177.
3. Engel WK, Gold GN, Karpati G. (1968) Type I fiber hypotrophy and central nuclei. A rare congenital muscle abnormality with a possible experimental model. Arch Neurol 18, 435-444.
4. Engel WK. (1962) The essentiality of histo- and cytochemical studies of skeletal muscle in the investigation of neuromuscular disease. Neurology 12, 778-794.
5. Engel WK, Cunningham GG. (1963) Rapid examination of muscle tissue-an improved trichrome method for fresh-frozen biopsy sections. Neurology 13, 919-923.
6. Padykula HA, Herman E. (1955) Factors affecting the activity of adenosine triphosphatase and other phosphatases as measured by histochemical techniques. J Histochem Cytochem 3, 161-169.
7. Drews GA, Engel WK. (1966) Reversal of the ATPase reaction in muscle fiber by EDTA. Nature 212, 1551-1553.
8. Engel WK. (1965) A clinical approach to the myopathies. Clin Orthop Rel Res 39, 6-18.
9. Engel WK. (1965) Muscle biopsy. Clin Orthop Rel Res 39, 80-105.
10. Engel WK. (1965) Diseases of the neuromuscular junction and muscle. In: Adams C (ed.). Neurohistochemistry. Elsevier Press, Amsterdam, pp. 622-672.
11. Engel WK. (1970) Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch Neurol 22, 97-117.
12. Engel WK. (1967) Focal myopathic changes produced by electromyographic and hypodermic needles. "Needle myopathy". Arch Neurol 16, 509-511.
13. Campa JF, Engel WK. (1970) Histochemistry of motor neurons and interneurons in the cat lumbar spinal cord. Neurology 20, 559-568.
14. Campa JF, Engel WK. (1970) Histochemical classification of anterior horn neurons. Neurology 20, 386.
15. Campa JF, Engel WK. (1971) Histochemical and functional correlations in anterior horn neurons of the cat spinal cord. Science 171, 198-199.
16. Karpati G, Engel WK. (1968) "Type grouping" in skeletal muscles after experimental reinnervation. Neurology 18, 447-455.
17. Hogenhuis LAH, Engel WK. (1965) Histochemistry and cytochemistry of experimentally denervated guinea pig muscle. I. Histochemistry. Acta Anat 69, 39-65.
18. Karpati G, Engel WK. (1967) Transformation of the histochemical profile of skeletal muscle by "foreign innervation". Nature 215, 1509-1510.
19. Karpati G, Engel WK. (1968) Correlative histochemical study of skeletal muscle after a suprasegmental denervation, peripheral nerve section, and skeletal fixation. Neurology 18, 681-692.
20. Karpati G, Engel WK. (1968) Histochemical investigation of fiber type ratios with the myofibrillar ATPase reaction in normal and denervated skeletal muscles in guinea pig. Am J Anat 122, 145-155.
21. Fenichel GM, Engel WK. (1963) Histochemistry of muscle in infantile spinal muscular atrophy. Neurology 13, 1059-1066.
22. Burke RE, Levine DN, Zajac F et al. (1971) Mammalian motor units: physiological-histochemical correlation in 3 types of cat gastrocnemius muscle. Science 174, 709-712.
23. Burke RE, Tsairis P, Levine N et al. (1973) Direct correlation of physiological and histochemical characteristics of motor units of cat triceps surae muscle. In: Desmedt JE (ed.). New Developments in Electromyography and Clinical Neurophysiology. Karger, Basel, pp. 23-30.
24. Warmolts JR, EngelWK. (1973) Correlation of motor unit behavior with histochemical and myofiber type in humans by open-biopsy electromyography. In: Desmedt JE (ed.). New Developments in Electromyography and Clinical Neurophysiology. Karger, Basel, pp. 35-40.
25. Warmolts JR, Engel WK. (1972) Open biopsy electromyography. I. Correlation of motor unit behavior with histochemical muscle fiber type in human limb muscle. Arch Neurol 27, 512-517.
26. Engel WK, Irwin RL. (1967) A histochemical-physiological correlation of frog skeletal muscle fibers. Am J Physiol 213, 511-518.
27. Brooke MH, Kaiser KK. (1970) Muscle fiber types: how many and what kind?. Arch Neurol 23, 369-379.
28. Askanas V, Engel WK. (1975) Distinct subtypes of type I fibers of human skeletal muscle. Neurology 25, 879-887.
29. Raffaello A, Milan G, Masiero E et al. (2010) JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J Cell Biol 191, 101-113.
30. Menzies FM, Hourez R, Imarisio S et al. (2010) Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Hum Mol Genet 19, 4573-4586.
31. Zhou X, Wang JL, Lu J et al. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543.
32. Brault JJ, Jespersen JG, Goldberg AL. (2010) Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem 285, 19460-19471.
33. Zhao J, Brault JJ, Schild A et al. (2008) Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 4, 378-380.
34. Sandri M, Lin J, Handschin C et al. (2006) PGC- 1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103, 16260-16265.
35. Mammucari C, Milan G, Romanello V et al. (2007) FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 6, 458-471.
36. Sacheck JM, Hyatt JP, Raffaello A et al. (2007) Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 21, 140-155.
37. Cohen S, Brault JJ, Gygi SP et al. (2009) During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185, 1083-1095.
38. Engel WK. (2010) Multi-microcramps (MMC) syndrome: a new pathogenic concept of subtle lower motor-neuron (LMN) lability causing very disturbing, continuing muscle pains, sometimes gratifying treatable - but often misinterpreted as mysterious "fibromyalgia" or "psychogenic". Neurology 74 (Suppl. 2), A465.
39. Engel WK. (1961) Muscle target fibers - a newly recognized sign of denervation. Nature 191, 389-390.
40. Mendell JR, Engel WK. (1971) The fine structure of type II muscle fiber atrophy. Neurology 21, 358-365.
41. Pleasure DE, Walsh GO, Engel WK. (1970) Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 22, 118-125.
42. Engel WK. (1965) Histochemistry of neuromuscular disease-significance of muscle fiber types. "Neuromuscular Diseases". In: Proceedings of the 8th International Congress of Neurology. Excerpta Medica Foundation, Amsterdam, vol. 2, pp. 67-101.
43. Engel WK. (1966) The multiplicity of pathologic reactions of human skeletal muscle. In: Luthy F, Bischoff A (eds). Proceedings of the 5th International Congress of Neurology. Excerpta Medica Foundation, Amsterdam, pp. 613-624.
44. Broccolini A, Engel WK, Askanas V. (1999) Localization of survival motor neuron protein in human apoptotic-like and regenerating muscle fibers, and neuromuscular junctions. Neuroreport 10, 1637-1641.
45. Altun M, Besche HC, Overkleeft HS et al. (2010) Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem 285, 39597-39608.
46. Terracciano C, Gattelli A, Lena E et al. (2010) Differential features of muscle atrophy in patients with osteoporosis and osteoarthritis. Acta Myologica 29, 88.
47. Allen DL, Cleary AS, Hanson AM et al. (2010) CCAAT/enhancer binding factor-delta expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am J Physiol Regul Integr Comp Physiol 299, R1592-R1601.
48. Allen DL, Loh AS. Post-transcriptional mechanisms involving microRNA-27a and b contribute to fastspecific and glucocorticoid-mediated myostatin expression in skeletal muscle. AmJ Physiol Cell Physiol 300, C124-C137.
49. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K. et al. (1998) Organization of the human myostatin gene and expression in healthy men and HIVinfected men with muscle wasting. Proc Natl Acad Sci USA 95, 14938-14943.
50. Jespersen JG, Nedergaard A, Andersen LL et al. (2011) Myostatin expression during human muscle hypertrophy and subsequent atrophy: increased myostatin with detraining. Scand J Med Sci Sports 21, 215-223.
51. Kamanga-Sollo E, Pampusch MS, White ME et al. (2003) Role of insulin-like growth factor binding protein (IGFBP)-3 in TGF-beta- and GDF-8 (myostatin)- induced suppression of proliferation in porcine embryonic myogenic cell cultures. J Cell Physiol 197, 225-231.
52. Ma K, Mallidis C, Bhasin S et al. (2003) Glucocorticoid- induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285, E363-E371.
53. Trendelenburg AU, Meyer A, Rohner D et al. (2009) Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 296, C1258-C1270.
54. Welle S, Burgess K, Mehta S. (2009) Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. Am J Physiol Endocrinol Metab 296, E567-E572.
55. Wojcik S, Nogalska A, Engel WK et al. (2008) Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy. Folia Morphol (Warsz) 67, 6-12.
56. Garcia PS, Cabbabe A, Kambadur R et al. (2010) Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg 111, 707-709.
57. Anderson SB, Goldberg AL, Whitman M. (2008) Identification of a novel pool of extracellular promyostatin in skeletal muscle. J Biol Chem 283, 7027-7035.
58. Lenk K, Schur R, Linke A et al. (2009) Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 11, 342-348.
59. Benny Klimek ME, Aydogdu T, Link M.J et al. (2010) Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 391, 1548-1554.
60. Gustafsson T, Osterlund T, Flanagan JN et al. (2010) Effects of 3 days unloading on molecular regulators of muscle size in humans. J Appl Physiol 109, 721-727.
61. Murphy KT, Cobani V, Ryall JG et al. (2011) Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. J Appl Physiol 110, 1065-1072.
62. Castillero E, Nieto-Bona MP, Fernandez-Galaz C et al. (2011) Fenofibrate, a PPAR alpha agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am J Physiol Endocrinol Metab 300, E790-E799.
63. Lopez-Menduina M, Martin AI, Castillero E et al. (2010) Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3. Am J Physiol Regul Integr Comp Physiol 299, R541-R551.
64. Moriscot AS, Baptista IL, Bogomolovas J et al. (2010) MuRF1 is a muscle fiber-type II associated factor and together with MuRF2 regulates type-II fiber trophicity and maintenance. J Struct Biol 170, 344-353.
65. Zhao J, Brault JJ, Schild A et al. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6, 472-483.
66. MacLean HE, Chiu WS, Notini AJ et al. (2008) Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 22, 2676-2689.
67. Glass DJ. (2010) Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 13, 225-229.
68. Sandri M. (2011) New findings of lysosomal proteolysis in skeletal muscle. Curr Opin Clin Nutr Metab Care 14, 223-229.
69. Mammucari C, Schiaffino S, Sandri M. (2008) Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 4, 524-526.
70. Wenz T, Rossi SG, Rotundo RL et al. (2009) Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA 106, 20405-20410.
71. Menconi MJ, Arany ZP, Alamdari N et al. (2010) Sepsis and glucocorticoids downregulate the expression of the nuclear cofactor PGC-1beta in skeletal muscle. Am J Physiol Endocrinol Metab 299, E533-E543.
72. Bossola M, Pacelli F, Tortorelli A et al. (2008) Skeletal muscle in cancer cachexia: the ideal target of drug therapy. Curr Cancer Drug Targets 8, 285-298.
73. Penna F, Costamagna D, Fanzani A et al. (2010) Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 5, e13604.
74. Schakman O, Gilson H, Thissen JP. (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197, 1-10.
75. Gilson H, Schakman O, Combaret L et al. (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148, 452-460.
76. Engel WK, McFarlin DE. (1966) Muscle lesions in myasthenia gravis. Ann NY Acad Sci 135, 68-78.
77. Bender AN, Ringel SP, Engel WK. (1976) The acetylcholine receptor in normal and pathologic states. Immunoperoxidase visualization of alphabungarotoxin binding at a light and electron-microscopic level. Neurology 26, 477-483.
78. Ringel SP, Bender AN, Engel WK. (1976) Extrajunctional acetylcholine receptors. Alterations in human and experimental neuromuscular diseases. Arch Neurol 33, 751-758.
79. Engel WK, Trotter JL, McFarlin DE et al. (1977) Thymic epithelial cell contains acetylcholine receptor. Lancet 1, 1310-1311.
80. Oldfors A, Moslemi AR, Jonasson L et al. (2006) Mitochondrial abnormalities in inclusion-body myositis. Neurology 66, S49-55.
81. Chomyn A, Attardi G. (2003) MtDNA mutations in aging and apoptosis. Biochem Biophys Res Commun 304, 519-529.
82. DiMauro S, Hirano M, Schon EA (eds) (2006) Mitochondrial Medicine. Informa Healthcare, London.
83. Romanello V, Guadagnin E, Gomes L et al. (2010) Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J 29, 1774-1785.
84. Hood D. (2010) Mitochondrial dysfunction in aging skeletal muscle: a potential therapeutic focus. Acta Myologica 29, 87.
85. Olson W, Engel WK, Walsh GO et al. (1972) Oculocraniosomatic neuromuscular disease with "ragged-red" fibers. Arch Neurol 26, 193-211.
86. Tsairis P, Engel WK, Kark AP. (1973) Familial myoclonic epilepsy syndrome associated with skeletal muscle mitochondrial abnormalities. Neurology 23, 408.
87. Lombes A, Mendell JR, Nakase H et al. (1989) Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol 26, 20-33.
88. Engel WK. (1971) "Ragged-red fibers" in opthamoplegia syndromes and their differential diagnosis. Excerpta Med Inter Cong Series 237, 28.
89. Engel WK, Eyerman EJ, Williams HE. (1963) Late-onset type of skeletal muscle phosphorylase deficiency: a new familial variety of completely and partially affected subjects. New Engl J Med 268, 135-137.
90. Askanas V, Engel WK, Alvarez RB. (1993) Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 43, 1265-1267.
91. Kula RW, Engel WK, Line BR. (1977) Scanning for soft-tissue amyloid. Lancet 1, 92-93.
92. Engel WK, Askanas V. (1998) Treatment of inclusion- body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms: personal experience. In: Askanas V, Serratice G, Engel WK (eds), Inclusion-body Myositis and Myopathies. Cambridge University Press, Cambridge, pp. 351-382.
93. Engel WK. (1977) Rod (nemaline) disease. In: Goldensohn ES, Appel SH (eds), Scientific Approaches to Clinical Neurology. Lea Febiger, Philadelphia, pp. 1667-1691.
94. Engel WK. (2007) Late-onset rod myopathy with monoclonal immunoglobulin can be treatable with IVIG. Neuromuscul Disord 17, 885.
95. Engel WK, Resnick JS. (1966) Late-onset rod myopathy - a newly recognized, aquired and progressive disease. Neurology 16, 308-309.
96. Mahajan S, Engel WK, Luthra I, Gupta V. (2011) Adult-onset rod myopathy syndrome (AORMS): sustained benefit from IVIG plus rituximab. Ann Neurol, in press.
97. Engel WK, Brooke MH, Nelson PG. (1966) Histochemical studies of denervated or tenotomized cat muscle. Illustrating difficulties in relating experimental animal conditions to human neuromuscular diseases. Ann NY Acad Sci 138, 160-185.
98. Murphy KT, Lynch GS. (2009) Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 14, 619-632.
99. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39, 412-423.
100. Kung T, Springer J, Doehner W et al. (2010) Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs 19, 579-585.
101. Thomas DR. (2010) Sarcopenia. Clin Geriatr Med 26, 331-346.
102. von Haehling S, Stepney R, Anker SD. (2010) Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol 144, 347-349.
103. Waters DL, Baumgartner RN, Garry PJ et al. (2010) Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging 5, 259-270.
104. Merry TL, Steinberg GR, Lynch GS et al. (2010) Skeletal muscle glucose uptake during contraction is regulated by nitric oxide and ROS independently of AMPK. AmJ PhysiolEndocrinolMetab 298, E577-E585.
105. Gielen S, Sandri M, Erbs S et al. (2011) Exerciseinduced modulation of endothelial nitric oxide production. Curr Pharm Biotechnol, in press.
106. D'Antona G, Nisoli E. (2010) mTOR signaling as a target of amino acid treatment of the age-related sarcopenia. Interdiscip Top Gerontol 37, 115-141.
107. Gentile MA, Nantermet PV, Vogel RL et al. (2010) Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of beta-catenin. J Mol Endocrinol 44, 55-73.
108. Wyce A, Bai Y, Nagpal S et al. (2010) Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function. Mol Endocrinol 24, 1665-1674.
109. Kota J, Handy CR, HaidetAMet al. (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 1, 6ra15.
110. Rodino-Klapac LR, Haidet AM, Kota J et al. (2009) Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39, 283-296.
111. Ryall JG, Church JE, Lynch GS. (2010) Novel role for beta-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin Exp Pharmacol Physiol 37, 397-401.
112. Lavenstein B, Engel WK, Reddy NB et al. (1979) Autoradiographic visualization of beta-adrenergic receptors in normal and denervated skeletal muscle. J Histochem Cytochem 27, 1308-1311.
113. Masiero E, Sandri M. (2010) Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 6, 307-309.
114. Larsen AE, Crowe TC. (2009) Effects of conjugated linoleic acid on myogenic and inflammatory responses in a human primary muscle and tumor coculture model. Nutr Cancer 61, 687-695.